BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DiaBeta (Glyburide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DiaBeta (Glyburide)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05426681-282@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:DiaBeta (Glyburide): Phase 1 readout est. (NCT05426681)
DESCRIPTION:DiaBeta (Glyburide)\, phase 1.\nStudy: Spinal Cord Injury Neuro
 protection With Glyburide\nEstimated primary completion: May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/glyburide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05426681
URL:https://assetmemo.bio/drug/glyburide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221799-282@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:DiaBeta (Glyburide): Phase 1 readout est. (NCT07221799)
DESCRIPTION:DiaBeta (Glyburide)\, phase 1.\nStudy: OER Glibenclamide for Ne
 uropathic Pain in Multiple Sclerosis\nEstimated primary completion: 1 Sept
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/glyburide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 21799
URL:https://assetmemo.bio/drug/glyburide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
